Technical Analysis for NAVB - Navidea Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 1.59 2.58% 0.04
NAVB closed down 1.27 percent on Tuesday, April 20, 2021, on 28 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical NAVB trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 2.58%
Down 3 Days in a Row Weakness 2.58%
Oversold Stochastic Weakness 2.58%
Narrow Range Bar Range Contraction 1.27%
Wide Bands Range Expansion 1.27%
Oversold Stochastic Weakness 1.27%
Outside Day Range Expansion -3.05%
Wide Bands Range Expansion -3.05%
Oversold Stochastic Weakness -3.05%
Narrow Range Bar Range Contraction -4.79%
Older End-of-Day Signals for NAVB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% 11 minutes ago
60 Minute Opening Range Breakout about 1 hour ago
Rose Above Previous Day's High about 1 hour ago
Up 3% about 1 hour ago
Up 2% about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Navidea Biopharmaceuticals, Inc. Description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company's radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule investigational radiopharmaceutical that is used in lymphatic mapping procedures, which are performed to help stage breast cancer and melanoma; and NAV4694, an F-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer's disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; and RIGScan, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. It has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Surgery Monoclonal Antibody Breast Cancer Melanoma Alzheimer's Disease Symptoms Parkinson's Disease Colorectal Cancer Medical Physics Dementia Biopharmaceuticals Tomography Movement Disorders Imaging Agent Metastasis Nuclear Medicine Positron Emission Tomography Cognitive Impairment Radiopharmaceuticals Iodine Medicinal Radiochemistry Positron Corporation

Is NAVB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.3569
52 Week Low 0.6751
Average Volume 313,341
200-Day Moving Average 2.70
50-Day Moving Average 2.21
20-Day Moving Average 1.88
10-Day Moving Average 1.72
Average True Range 0.15
ADX 23.54
+DI 11.52
-DI 28.71
Chandelier Exit (Long, 3 ATRs ) 1.96
Chandelier Exit (Short, 3 ATRs ) 1.95
Upper Bollinger Band 2.27
Lower Bollinger Band 1.49
Percent B (%b) 0.07
BandWidth 41.20
MACD Line -0.17
MACD Signal Line -0.15
MACD Histogram -0.0267
Fundamentals Value
Market Cap 41.37 Million
Num Shares 26.7 Million
EPS -1.24
Price-to-Earnings (P/E) Ratio -1.25
Price-to-Sales 64.17
Price-to-Book 4.47
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.67
Resistance 3 (R3) 1.67 1.63 1.65
Resistance 2 (R2) 1.63 1.60 1.63 1.64
Resistance 1 (R1) 1.59 1.58 1.61 1.59 1.64
Pivot Point 1.55 1.55 1.56 1.55 1.55
Support 1 (S1) 1.51 1.52 1.53 1.51 1.46
Support 2 (S2) 1.47 1.50 1.47 1.46
Support 3 (S3) 1.43 1.47 1.45
Support 4 (S4) 1.43